Stay alert, beware of scamsters - know more

NSEBSE
NSEBSE
noteThere is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
1D
1W
1M
1Y
3Y
5Y
Max
Open525.9
High531.05
Low524.6
Prev. Close524.4
Avg. Traded Price527.51
Volume35,051

MARKET DEPTH

info2
Total bid46635.00
Total ask52277.00
OrdersQtyBid
541526.2
210526.15
15526.1
315526.05
222526
AskQtyOrders
526.626
526.75552
526.8330
526.85329
526.9552

HIGH/LOW

info2
1d
1w
1m
3m
52w

LOW/HIGH

551.752 days ago
565.002 days ago
arrow

LOWER/UPPER CIRCUITS

445.80
668.60
arrow
Thyrocare Technologies Ltd Stock performance
arrow

KEY OBSERVATIONS

info
positive
negative
neutral

Our researchers has found no immediate positive insights for this stock. We'll update this space as soon as we find something.

LONG-TERM PRICE ANALYSIS

info
Stock return5Y CAGR : 2.02%
Net profit growth 5Y CAGR : 0.96%

About Thyrocare Technologies Limited

 

Thyrocare Technologies Limited is a listed diagnostics company headquartered in Navi Mumbai, delivering IT-enabled, fully automated laboratory services since 1996 and incorporated on January 28, 2000. It operates a nationwide network of 29 NABL-accredited laboratories comprising 2 Central Processing Labs, 19 Regional Processing Labs, 2 Zonal Processing Labs and 6 Satellite Processing Labs, with a growing international footprint that includes a laboratory in Tanzania. Its consumer and clinician-focused portfolios span Aarogyam (preventive health), Jaanch (doctor-curated diagnostics) and Her Check (women’s wellness). The company reports industry-leading turnaround, releasing 98% of reports within six hours. Equity shares are listed on NSE and BSE. Thyrocare offers over 920 diagnostic tests delivered to homes across 4,600 pin codes and provides ECG at Home services in 1,000+ pin codes. The company has 3 subsidiaries. Key milestones in the latest year include strategic acquisitions, expansion of accredited labs and commissioning of the Tanzania lab.

 

Products and services include diagnostic testing services, imaging services and sale of testing equipment and consumables (including glucometers and glucostrips under the Sugarscan brand).

 

Thyrocare Technologies Limited Business Segments

  • Pathology: 89.22% of revenue
  • Radiology: 7.90%
  • Materials & Others: 2.89%

 

Thyrocare Technologies Limited Key Management

  • Rahul Guha – Chairman, Managing Director and CEO
  • Alok Kumar Jagnani – Chief Financial Officer
  • Brijesh Kumar – Company Secretary and Compliance Officer

 

Latest Updates on Thyrocare Technologies Limited

  • Acquisitions: Thyrocare acquired the diagnostics business of Polo Labs Private Limited through a Business Transfer Agreement, expanding presence across Punjab, Haryana and Himachal Pradesh. It also completed the acquisition of the clinical diagnostic business of Vimta Labs Limited on October 11, 2024, strengthening operations across multiple cities in southern and eastern India.
  • International expansion: Thyrocare Laboratories (Tanzania) Limited went live in March 2024, processed its first sample in April 2024 and has partnered with 100+ healthcare facilities in Dar es Salaam.
  • Network and quality: NABL-accredited labs increased from 25 to 29. The company continues to maintain high standards with 100% NABL accreditation across its 29 owned labs in India, alongside long-standing CAP recognition.
  • Service reach: ECG at Home now covers 1,000+ pin codes with a dedicated fleet of ECG phlebotomists; home sample collection spans over 4,600 pin codes with 920+ tests available.
  • Operating scale: Around 167.9 million tests were conducted during the year, reflecting 14% year-on-year growth.
  • Governance update: The company disclosed material related party transactions with its holding company, Docon Technologies Private Limited, covering diagnostic testing services and sale of consumables, with shareholder approval obtained earlier.
personal

Grow your wealth with more research recommendations

+91

Frequently Asked Questions

For Q4 FY26, Thyrocare Technologies Ltd reported: Revenue (Net Sales): ₹2106.70 Cr - Up 15.45% year-on-year from ₹1824.80 Cr in Q3 FY26. Net Income (PAT): ₹435.80 Cr - Up 66.65% year-on-year from ₹261.50 Cr in Q3 FY26.

The intraday high for Thyrocare Technologies Ltd on the NSE today (04 Jul 2026) was ₹565.00. This compares to the 52-week high of ₹578.25 recorded on 09 Jun 2026. Today's high was -2.29% below the 52-week high.

As of 04 Jul 2026, the share price of Thyrocare Technologies Ltd is ₹555.00 on the NSE and ₹553.10 on the BSE. The stock opened at ₹557.20, touched a high of ₹565.00 and a low of ₹540.95 during today's session.

Over the last 6 months, Thyrocare Technologies Ltd has given a return of 20.29%. The stock was priced at ₹461.90 on 05 Jan 2026 and has Rise to ₹555.00 as of 04 Jul 2026, a change of ₹93.10 per share.

Yes,Thyrocare Technologies Ltd has declared a consistent dividend every year over the past 5 years. The company paid a total dividend of 86.00 per share between FY2022 and FY2026, with the most recent dividend of ₹7.00 per share for May 26, with an ex-dividend date of 23 Jun 2026. At the current market price of ₹555.00, the trailing dividend yield of Thyrocare Technologies Ltd stands at 35.00%.

Thyrocare Technologies Ltd has delivered a 25.07% absolute return over the past 5 years, equivalent to a CAGR of 4.58% per annum. The stock was priced at ₹443.75 in Jul 2021 and has risen to ₹555.00 as of 04 Jul 2026. An investment of ₹1,00,000 in Thyrocare Technologies Ltd five years ago would be worth ₹1,25,070.00 today.

The all-time high (ATH) for Thyrocare Technologies Ltd was ₹558.40, recorded on 23 Jun 2026. At the current price of ₹555.00, the stock is trading 0.61% below its all-time high. The all-time low recorded was ₹138.43 on 30 Jul 2019.

Thyrocare Technologies Ltd has delivered 62.91% return over the last 52 weeks. During this period, the stock hit a 52-week high of ₹578.25 on 09 Jun 2026 and a 52-week low of ₹335.88 on 07 Jul 2025. It is currently trading at ₹555.00 as of 04 Jul 2026.

Thyrocare Technologies Ltd has delivered a return of 46.42% over the last 3 months. The stock was trading at ₹379.45 on 06 Apr 2026 and is currently at ₹555.00 as of 04 Jul 2026, reflecting a Gain of ₹175.55 per share over this period.

The intraday low for Thyrocare Technologies Ltd on the NSE today was ₹540.95. The stock's 52-week low stands at ₹335.88, recorded on 07 Jul 2025. Today's low is 61.05% above the 52-week low, indicating the stock is trading well above its yearly lows.

+91
Offer Banner Trigger
Offer Banner

Open a FREE Demat Account

+91